CDKN2A and tubular adenocarcinoma: The other two patients with tubular carcinomas had KRAS and/or CDKN2A/p16 alterations, but no loss of SMAD4 or TP53 mutations (details see Table 4), and survived for >55.3 and 19.3 months.